Log in


G
M
T
Y
文本转语音功能仅限200个字符


Hosted by 

DahShu's virtual journal club is held monthly to promote the most cutting edge research in the fields of data sciences. Click to download presentation slides and seminar recording materials for each event.

Chair and Associate Chairs

G
M
T
Y
文本转语音功能仅限200个字符


Rui (Sammi) Tang

Chair

G
M
T
Y
文本转语音功能仅限200个字符

Jiarui Zhang

Associate Chair

G
M
T
Y
文本转语音功能仅限200个字符
选项 : 历史 : 反馈 : Donate 关闭

Jing Lu

Associate Chair

G
M
T
Y
文本转语音功能仅限200个字符


Upcoming events

    • Fri, June 25, 2021
    • 09:00 - 10:00 (PDT)
    Register

    Fri, June 25, 2021, 09:00 – 10:00AM (PDT), 12:00 – 1:00PM (EST)

    Abstract 

    Recently, new FIRRMA final regulations have been published.  The webinar will review how these regulations came to be, how they operate and how they are impacting the investment world, in both intended and unintended ways.

     

    Recently, new FIRRMA final regulations have been published to further clarify the definition of “sensitive personal data” which was previously left to be developed by CFIUS. The final regulations clarify the provision on genetic testing in two ways: 1) by focusing the definition on genetic tests and 2) by limiting the coverage of the rule to identifiable data. The final regulations implement CFIUS’s jurisdiction over 11 specific categories of sensitive personal data, including health, biometric, and genetic data. CFIUS now have expanded jurisdiction over U.S. companies that collect or maintain records relating to a U.S. citizen's genetic information, such as a genetic test or individual or family history, which biotechnology or life sciences companies might collect and could lead to CFIUS review. CFIUS will closely monitor biotechnology and life sciences companies that operate in these relevant sectors and identify transactions in which a foreign investment raises a national security concern.


    Speaker:


    Ed Lebow: Ed Lebow has been skillfully representing clients in international trade cases for more than 30 years. Through years of providing insightful counsel to both domestic and foreign companies, Ed has developed a broad and comprehensive perspective, which he brings to his clients’ business needs.

    Ed obtains relief for U.S. industries injured by dumped or subsidized imports and successfully defends foreign companies against such actions. He is especially adept in advising clients on how to comply with U.S. trade laws and avoid costly legal proceedings. Ed regularly deals with OFAC sanctions, export controls, NAFTA, anti-bribery issues under the Foreign Corrupt Practices Act (FCPA), and customs matters. Ed has guided both foreign buyers and domestic sellers of companies with sensitive technologies through the inter-agency Committee on Foreign Investment in the United States (CFIUS). Ed has also represented both U.S. and foreign clients before Congress.

    Prior to private practice, Ed served as an Assistant General Counsel of the U.S. International Trade Commission. Ed also headed the ITC’s Section 337 staff office. Drawing on this experience, Ed is well-versed in handling Section 337 proceedings involving patent infringement and other unfair trade practices.


    Angela Kwok is currently the General Counsel of Leszath Pharma, Inc, a pharmaceutical start-up company. Before that, she worked for several law firms in Silicon Valley. She is an experienced corporate attorney who provides strategic solutions to clients in Silicon Valley/San Francisco Bay Area, specializing in startups, venture capital financing, M&A, private equity/venture capital fund formation and CFIUS issues related to cross-border transactions.


    Strategic Alliance:


Past events

Mon, May 24, 2021 Automated Image Labeling for Medical Imaging AI
Fri, April 23, 2021 Dynamic Data Monitoring of Ongoing Clinical Trials
Fri, March 19, 2021 IP Legal Considerations for Precision Medicine and Digital Health Companies
Fri, February 19, 2021 Machine Learning Based Integrative Multi-Omics Analysis— Presented by Global Champion of All Three PrecisionFDA AI Challenges
Fri, January 29, 2021 How to quantify and interpret the treatment effects for comparative clinical studies of COVID-19 diseases?
Fri, November 13, 2020 Telehealth and Other Advancements in Healthcare Technology Spurred by COVID-19
Fri, October 02, 2020 A New Measurements-Based Approach to Machine Learning for Bioinformatics
Fri, September 25, 2020 Under the hood of 1Point3Acres COVID-19 map & tracker
Fri, August 28, 2020 Demystifying the drop-outs in single cell RNA-seq data
Fri, July 17, 2020 Using multiple natural experimental designs to triangulate the impact of a policy change
Fri, May 29, 2020 How AI is changing the financial service industry
Fri, March 13, 2020 AI Drug Discovery and Repurposing
Fri, February 28, 2020 The i3+3 Design: A Rule-Based Dose-Finding Approach for Phase I Trials
Fri, December 13, 2019 Statistical Considerations in the Clinical Development of Novel Cancer Therapies
Fri, November 15, 2019 15 Tips on Making Better Use of R Markdown
Wed, October 02, 2019 Principles of Data Science
Fri, September 20, 2019 AI Derived Personalized Solution: The Key Driver in the Era of Digital Health
Fri, August 09, 2019 Scalable Automatic Machine Learning with H2O
Fri, June 07, 2019 Network Meta-Analysis for Decision-Making
Fri, May 03, 2019 Global Prediction of Gene Regulatory Landscape Using Bulk and Single-Cell RNA-seq
Fri, March 08, 2019 Innovative adaptive design for immune-oncology trials
Fri, February 22, 2019 Survival analysis methods for non-proportional hazards
Tue, January 08, 2019 Design of Dose-Response Clinical Trials
Fri, November 16, 2018 Neyman-Pearson Classification Algorithms and NP Receiver Operating Characteristics
Fri, October 19, 2018 Machine Learning in Medical Imaging: the Challenge and Opportunity in Drug Development and Precision Medicine
Fri, September 14, 2018 Disease Heritability Inferred from Familial Relationships Reported in Medical Records
Fri, July 20, 2018 Big Data and Artificial Intelligence in Healthcare
Fri, May 25, 2018 The Genomic Landscape and Pharmacogenomic Interactions of Clock Genes in Cancer Chronotherapy.
Mon, May 21, 2018 Estimation of Treatment Effect under Non-Proportional Hazards
Mon, May 21, 2018 Subgroup Identification in Drug Development: Are Post-Selection Adjustments of Efficacy Useful?
Mon, April 30, 2018 An accurate and robust imputation method scImpute for single-cell RNA-seq data
Fri, March 30, 2018 Genome-scale signatures of gene interaction from compound screens predict clinical efficacy of targeted cancer therapies.
Thu, February 22, 2018 Expression Recovery in Single Cell RNA Sequencing
Wed, January 31, 2018 Single-cell transcriptomics reconstructs fate conversion from fibroblast to cardiomyocyte
Thu, October 19, 2017 Statistical Challenges in Immuno-Oncology, a Cellular Therapies Perspective
Tue, September 26, 2017 Big-Data Analysis Points Toward a New Cancer Therapeutic Discovery Approach
Thu, September 14, 2017 Software Patenting: The Current State of the Law
Mon, August 21, 2017 The Asthma Mobile Health Study, a Large Scale Clinical Study Using ResearchKit

文本转语音功能仅限200个字符
选项 : 历史 : 反馈 : Donate 关闭
G
M
T
Y
文本转语音功能仅限200个字符


文本转语音功能仅限200个字符
选项 : 历史 : 反馈 : Donate 关闭


@Dahshu 2020

文本转语音功能仅限200个字符
选项 : 历史 : 反馈 : Donate 关闭
G
M
T
Y
文本转语音功能仅限200个字符
选项 : 历史 : 反馈 : Donate 关闭
G
M
T
Y
文本转语音功能仅限200个字符
Powered by Wild Apricot Membership Software